Glenmark and MeyerZall Laboratories to offers topical dermatology products in South Africa

Glenmark Pharmaceuticals South Africa today announced the expansion of its topical dermatology portfolio with the signing a 10-year marketing and distribution rights agreement with MeyerZall Laboratories.

Therapeutic areas covered by this distribution agreement include psoriasis, fungal infections of the skin and inflammation with the following products now falling into the Glenmark portfolio; Linotar Gel 1, Covarex and Athru-Derm, all with unique patented delivery systems which are available for distribution through the South African public health distribution network.

"With the addition of these products to Glenmark''s portfolio, we are now able to offer one of the widest topical dermatology baskets in the South African market,: said A S Mohanty, director, formulations, Glenmark Pharmaceuticals Ltd. "This will significantly add to our existing range of Synalar, Synalar-C, Synalar-N and Naseptin, and create a significant niche in the area of dermatology for Glenmark in South Africa."

In December 2005, Glenmark Pharmaceuticals Ltd acquired Bouwer Bartlett Pty Ltd, a South African sales and marketing company, through Glenmark Pharmaceuticals S,A, its wholly owned Swiss subsidiary.